Drug Trial Radar · NCT04345367
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
Last checked: Nov 19, 2026Latest source record: Jul 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
727
Actual
Start
Jun 11, 2020
Primary completion
Jul 13, 2021
Study completion Jul 13, 2021
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous injection every other week (as per label guidelines) in adult participants on background topical therapy, with moderate to severe AD. The treatment duration is 26 weeks. A total of approximately 600 participants will be enrolled from approximately 220 sites globally. Approximately 600 participants will be randomly assigned to study intervention. There are primary efficacy assessments at Week 2 and Week 4, and a key secondary efficacy assessment at Week 16. Efficacy and safety endpoints will be assessed throughout the entire study. Exploratory endpoints related to hand eczema efficacy will be assessed throughout the study.
Conditions
- Atopic Dermatitis
Interventions
Abrocitinib 200 mgDrug
Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.
Dupilumab 300 mgCombination product
Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2Time frame: Week 2
- Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4Time frame: Week 4
Locations
151 sites in 15 countries. Site status is shown where the registry gives one.
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama
Clinical Research Center Of Alabama
Birmingham, Alabama
Alliance Dermatology & MOHS Center, PC
Phoenix, Arizona
First OC Dermatology
Fountain Valley, California
Ark Clinical Research
Long Beach, California
Beach Allergy and Asthma Specialty Group, A Medical Corporation
Long Beach, California
Wallace Medical Group, Inc
Los Angeles, California
Empire Clinical Research
Pomona, California
MedDerm Associates
San Diego, California
University of California San Diego Dermatology
San Diego, California
University Clinical Trials Inc.
San Diego, California
Synergy Dermatology
San Francisco, California
Wolverine Clinical Trials, Llc
Santa Ana, California
Clinical Science Institute
Santa Monica, California
Skin Care Research, LLC
Boca Raton, Florida
Olympian Clinical Research
Largo, Florida
Miami Dermatology & Laser Research, LLC
Miami, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Accel Research Sites - Pure Skin Dermatology & Aesthetics
Orlando, Florida
Clinical Research Trials of Florida, Inc.
Tampa, Florida
Olympian Clinical Research
Tampa, Florida
Integrated Clinical Research
West Palm Beach, Florida
One Health Research Clinic
Norcross, Georgia
Sneeze, Wheeze & Itch Associates, LLC
Normal, Illinois
Dundee Dermatology
West Dundee, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
The South Bend Clinic Center for Research
South Bend, Indiana
Epiphany Dermatology of Kansas, LLC
Overland Park, Kansas
Avant Research Associates, LLC
Crowley, Louisiana
MetroBoston Clinical Partners, LLC
Brighton, Massachusetts
Onyx Clinical Research
Flint, Michigan
Linden Road Imaging Center
Flint, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Regional Medical Imaging, P.C. ( Local X-Ray)
Royal Oak, Michigan
Revival Research Institute, LLC
Troy, Michigan
Skin Specialists, PC
Omaha, Nebraska
Vivida Dermatology
Las Vegas, Nevada
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Boice-Willis Clinic, PA
Rocky Mount, North Carolina
Carolina Research Center, Inc.
Shelby, North Carolina
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.